MediGene AG
Description MediGene AG, a biotechnology company, engages in the research and development of drugs for the treatment of cancer and autoimmune diseases in Europe and the United States. The company operates in two segments, Marketed Products and Drug Candidates. The Marketed Products segment offers Veregen, an ointment used to treat external genital warts. The Drug Candidates segmentÂ’s pipeline includes EndoTAG-1, a drug candidate that has completed two Phase II clinical trials to treat the pancreatic and breast cancer; RhuDex, which is in Phase II clinical trials for the oral treatment of autoimmune diseases; and Adeno-associated virus-like particles potential as prophylactic and therapeutic vaccines against cancer and infections. The company is headquartered in Martinsried, Germany. To view the detailed information, you need to SUBSCRIBE with us. |
 |